Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 4/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19108250 | 0.92 | ALOX5 (0.38) | ALOX5PARP14PRKDCALKALDH1A1 | |
| SCHEMBL17944393 | 0.92 | ALOX5 (0.42) | ALOX5PARP14PRKDCALDH1A1MAPT | |
| SCHEMBL19109744 | 0.92 | ALOX5 (0.35) | ALOX5PRKDCALKF9 | |
| SCHEMBL19109724 | 0.91 | ALOX5 (0.38) | ALOX5PARP14PRKDCALKALDH1A1 | |
| SCHEMBL19108346 | 0.90 | ALOX5 (0.37) | ALOX5PARP14PRKDCALKALDH1A1 | |
| SCHEMBL19109762 | 0.90 | ALOX5 (0.35) | ALOX5PRKDCALK | |
| SCHEMBL19110293 | 0.90 | ALOX5 (0.40) | ALOX5PARP14PRKDCALDH1A1MAPT | |
| SCHEMBL19108304 | 0.89 | ALOX5 (0.36) | ALOX5PARP14ALKMAPT | |
| SCHEMBL24341061 | 0.89 | ALOX5 (0.38) | ALOX5PARP14PRKDCALKALDH1A1 | |
| SCHEMBL19108395 | 0.89 | ALOX5 (0.38) | ALOX5PARP14PRKDCALKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11276827-B2 | Condensed cyclic compound and an organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-03-15 | — | — | US | disclosed |
| US-20170200905-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-13 | — | — | US | disclosed |
| US-20170200905-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170200905-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNA1 | ALOX5 1871/4885PARP14 3128/4885PRKDC 4792/4885 |
| US-11276827-B2 | Condensed cyclic compound and an organic light-emitting device including the same | CRY1, CRY2, CCNA1 | ALOX5 1871/4885PARP14 3128/4885PRKDC 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.